brighter tone commentari aesthet anxieti
somewhat allevi rais pt
tough eye holx cynosur aesthet busi
go cyno sale exceed street bar
think share may enjoy small relief ralli
wednesday think investor also want see long-term growth
compani core busi remain solid nice revenu
beat breast strong blood screen sale also
encourag seem like stabil gyn surgic divis
beyond result pick faxitron bioptic
announc new cfo intern promot prior cfo move
agil view revenu guidanc set street estim
may slightli conserv view posit quarter
overal rais pt previous base
mo adj ep estim
aesthet commentari far confid last quarter
recent fda scrutini clinic evid market around
technolog target vagin rejuven market may caus
slight soft near term management believ emerg
market leader space model sequenti step-down
cyno sale next quarter reflect dynam season
slightli increas cyno forecast beyond dont
expect substanti market reaction fda nois
acquir faxitron bioptic busi repres sale
last fy increas intervent breast solut revenu
transact expect accret ep start
tariff mention briefli chines sale
total revenu expect materi impact
sale oper
valuat rate buy pt base
month adj ep estim risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
report total revenu beat consensu
estim btig consensu beat came strong
result breast health diagnost mainli blood screen
busi aesthet divis gyn surgic sale exactli line
forecast though estim exact breakdown novasur
myosur base report growth rate
 gross margin bp lighter model sg spend
percentag revenu higher expect spend
lower ad oper margin bp forecast
share count lower model thank part share
repurchas ad one penni non-gaap ep adj ep
three cent higher estim
actualsbtig estimate variancebreast sale sale cytolog perinat molecular diagnost blood screen surgic sale novasur myosur sale sale revenu market admin incom incom gross bp sg spend bp spend bp ebit bp tax bpssourc btig estim compani filingsvari
trim aesthet revenu estim assum slight
sequenti step due season near-term scrutini mona lisa
trim estim busi segment slightli add
faxitron revenu intervent breast solut divis
forecast revenu top end guidanc
rang adjust share count adjust share buy-back
share count guidanc reduc gross margin increas sg
spend decreas spend arriv ep estim
midpoint guidanc rang forecast sale
top end guidanc rang lower end guidanc
make chang outlook incorpor slight
increas aesthet sale add faxitron revenu increas sg
spend slightli decreas interest incom reflect potenti
cost relat acquisit addit share count lower
previou model due quarter share repurchas total revenu
increas chang result one
penni increas ep three cent increas ep
rate buy pt base month
adjust ep estim feel slight increas valuat multipl
previous justifi cynosur divis shown sign
recoveri still use multipl comp group reflect
compani slightli lower revenu growth investor sentiment take
time turn risk rate price target includ cyno result
adopt chang reimburs diagnost price
slowdown novasur competit success integr cyno
revenu incom btig estim compani filingsnewold chang
ntm entm eepsrevsdentsplyxraynot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
holog incom million except total y/i sell gener oper interest incom incom tax incom share net calendar loss oper btig estim compani report
holog revenu million except selenia dffm asp y/i selenia tomo asp y/i tomo instal y/i breast imag revenu system y/i breast imag y/i imag y/i breast y/i y/i breast y/i breast revenu y/i breast revenu y/i y/i y/i y/i diagnost y/i y/i y/i y/i gyn surgic y/i skelet y/i y/i y/i y/i aesthet revenu y/i y/i revenu y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
